PharmaDepth

Company profile

PFIZER INC

NYSE:PFEBiotechnology: Pharmaceutical Preparations

Drug pipeline (649)

AssetStageRevenueTrialsStatus
Tafamidis meglumineapproved$1.8BQ2 20268approved
Palbociclibapproved$1.1BQ2 202628approved
Rimegepant sulfateapproved$421.0MQ2 20260—
LORLATINIBapproved$354.0MQ2 202616approved
Methylprednisoloneapproved$339.0MFY 20237approved

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (3536)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00139750phase2completed2004-12-01—Pfizer12 Week Evaluation of the Safety and Efficacy of 3 Doses of CP-526,555 and Placebo for Smoking Cessation
NCT00150254phase2completed2001-09-01—Pfizer12 Week Evaluation of the Safety and Efficacy of 4 Dosing Strategies of CP-526,555 and Placebo for Smoking Cessation.
NCT00150228phase2completed2001-12-01—Pfizer12 Week Evaluation of the Safety and Efficacy of a Flexible Dose of CP-526,555 and Placebo for Smoking Cessation
NCT00159757phase4terminated2003-11-01—Pfizer's Upjohn has merged with Mylan to form Viatris Inc.12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
NCT00473525phase2completed2007-07-012008-06-01Pfizer12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

FDA applications (1086)

ApplicationApprovedTypeApplicantProducts
ANDA 2174592025-09-11ANDAHOSPIRA INC
BLA 7613692024-10-11BLAPfizer Inc.
BLA 1257862024-04-25BLAPfizer Inc.
NDA 2174392024-03-07NDAPFIZER INC
BLA 1257702023-10-20BLAPfizer Ireland Pharmaceuticals Unlimited Company